- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: Liposome.
Displaying page 1 of 2.
EudraCT Number: 2014-005021-13 | Sponsor Protocol Number: MK-0991-044 | Start Date*: 2015-04-03 |
Sponsor Name:Merck & Co., Inc. | ||
Full Title: A Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus (Amphotericin B) Liposome for Injection as Empirical Therapy in P... | ||
Medical condition: Empirical Therapy in Pediatric Patients | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-003275-19 | Sponsor Protocol Number: 402-C-322 | Start Date*: 2013-01-29 | |||||||||||
Sponsor Name:Pacira Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Intercostal Nerve Block with Liposome Bupivacaine in Subjects Undergo... | |||||||||||||
Medical condition: Intercostal Nerve Block for Posterolateral Thoracotomy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001349-14 | Sponsor Protocol Number: LEP-ETU-102B | Start Date*: 2004-11-18 | |||||||||||
Sponsor Name:NeoPharm, Inc. | |||||||||||||
Full Title: A Study Extension to Evaluate the Safety and Tolerability of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients that Completed Study LEP-ETU-102A | |||||||||||||
Medical condition: advanced non-hematologic malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003585-14 | Sponsor Protocol Number: D-US-60010-001 | Start Date*: 2020-04-08 | |||||||||||
Sponsor Name:Ipsen Bioscience, Inc. | |||||||||||||
Full Title: An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not prev... | |||||||||||||
Medical condition: Previously Untreated, Metastatic Pancreatic Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) HU (Completed) BE (Ongoing) AT (Ongoing) FR (Ongoing) PT (Completed) GR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004261-26 | Sponsor Protocol Number: MM-398-01-03-04 | Start Date*: 2018-10-29 | |||||||||||
Sponsor Name:Ipsen Bioscience, Inc | |||||||||||||
Full Title: RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based... | |||||||||||||
Medical condition: Small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Ongoing) ES (Ongoing) HU (Completed) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000994-35 | Sponsor Protocol Number: 06032017 | Start Date*: 2018-08-02 | |||||||||||
Sponsor Name:Hospital General Universitario de Alicante | |||||||||||||
Full Title: Study of tolerability of iron liposome compared to ferrous sulphate in pregnant women with iron deficiency anemia. | |||||||||||||
Medical condition: Iron deficiency anaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000609-36 | Sponsor Protocol Number: FIFERM03 | Start Date*: 2019-12-16 |
Sponsor Name:Hospital Vall d´Hebrón | ||
Full Title: Study of the use of Liposomal Iron in the treatment of iron deficiency anemia in pregnancy and puerperium | ||
Medical condition: Iron deficiency anemia | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003079-16 | Sponsor Protocol Number: INS-416 | Start Date*: 2021-02-08 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen ... | |||||||||||||
Medical condition: Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) FR (Ongoing) DE (Ongoing) AT (Ongoing) HU (Completed) GR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005544-17 | Sponsor Protocol Number: EMR 200038-010 | Start Date*: 2009-08-20 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A randomized, double-blind, controlled phase III study of Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy... | |||||||||||||
Medical condition: post-menopausal women with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive, inoperable locally advanced, recurrent, or metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DE (Prematurely Ended) HU (Completed) NL (Completed) IE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) FR (Completed) IT (Prematurely Ended) SK (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002402-36 | Sponsor Protocol Number: 651 | Start Date*: 2015-08-27 |
Sponsor Name:Sint Maartenskliniek | ||
Full Title: Pharmacokinetic Profile of Liposome Bupivacaine (Exparel®) after Perineural Admission in the Interscalene Groove for Primary Total Shoulder Arthroplasty. | ||
Medical condition: patients receiving a primary total shoulder arthroplasty | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000173-21 | Sponsor Protocol Number: (no code number allocated) | Start Date*: 2005-11-28 |
Sponsor Name:Dieter Hoelzer, MD,PhD | ||
Full Title: A PHASE II CLINICAL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DEPOCYTE® (CYTARABINE LIPOSOME INJECTION) FOR THE TREATMENT OF CNS RELAPSE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR H... | ||
Medical condition: Acute lymphoblastic leukaemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-001842-34 | Sponsor Protocol Number: DOXIL-MMY-3001 | Start Date*: 2004-11-29 |
Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development | ||
Full Title: A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | ||
Medical condition: Recurred or relapsed multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) GB (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000339-28 | Sponsor Protocol Number: CA025-006 | Start Date*: 2018-10-01 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination with Nivolumab (BMS-936558) with and without chemotherapy in Patients with Advanced Pancreatic Cancer | |||||||||||||
Medical condition: Advanced Pancreatic Cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-006109-19 | Sponsor Protocol Number: STM01-102 | Start Date*: 2006-09-08 | |||||||||||
Sponsor Name:Sopherion Therapeutics, Inc. | |||||||||||||
Full Title: A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel versus Trastuzumab and Paclitaxel for First line Therapy of Metastatic Breast Cancer | |||||||||||||
Medical condition: HER2+ Metastatic Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: PT (Completed) DE (Completed) ES (Prematurely Ended) GB (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002545-42 | Sponsor Protocol Number: INS-415 | Start Date*: 2021-02-08 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous M... | |||||||||||||
Medical condition: Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Completed) HU (Completed) AT (Completed) NL (Completed) GR (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003435-11 | Sponsor Protocol Number: VL2397-201 | Start Date*: 2018-08-14 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Vical Incorporated | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Immunocompromised Adults | ||||||||||||||||||||||||||||||||||||||
Medical condition: Invasive Aspergillosis | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-006652-19 | Sponsor Protocol Number: NILG-ALL 10/07 | Start Date*: 2008-02-06 | |||||||||||
Sponsor Name:NILG | |||||||||||||
Full Title: A Randomized Pilot Study on Central Nervous System (CNS) Prophylaxis with Liposome-Encapsulated Cytarabine (DepoCyte) in a Population of Adult Patients with Acute Lymphoblastic Leukemia (ALL) Treat... | |||||||||||||
Medical condition: 2. Diagnosis of untreated ALL with B-/T-precursor phenotype or B/T-LL, either de novo or secondary to chemo-radiotherapy for other cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004495-21 | Sponsor Protocol Number: GS-MC-131-0165 | Start Date*: 2006-09-07 | |||||||||||
Sponsor Name:Gilead Sciences GmbH | |||||||||||||
Full Title: Pilot study on safety of four weekly administrations of 7 mg/kg of liposomal amphotericin B (AmBisome®) in antifungal primary prophylaxis treatment of elderly patients with acute lymphoblastic leuk... | |||||||||||||
Medical condition: Antifungal prophylaxis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000961-22 | Sponsor Protocol Number: 16/009U | Start Date*: 2016-11-14 |
Sponsor Name:Ziekenhuis Oost-Limburg | ||
Full Title: Quality of analgesia after ultrasound-guided specific blocks of the distal tibial and deep peroneal nerves with 15 mL of a 50:50 mixture bupivacaine 0.5% and liposome bupivacaine (Exparel®) )1.3% ... | ||
Medical condition: Hallux valgus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003604-31 | Sponsor Protocol Number: PREFER-HF | Start Date*: 2017-02-09 |
Sponsor Name:José Luis Morales Rull, Institut de Recerca Biomédica Lleida IRB Hospital Arnau de Vilanova Servicio de Medicina Interna | ||
Full Title: Effects of intravenous iron therapy with ferric carboxymaltose compared with oral iron therapy in heart failure with preserved ejection fraction and iron deficiency. ( PREFER-HF) | ||
Medical condition: Patients with heart failure with preserved ejection fraction ( HFpEF) and iron deficency anemia. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.